Uncover hidden gems in the stock market with the 'Undercovered Dozen' series featuring undervalued stocks with potential for ...

In a report released yesterday, Charlie CY Yang from Bank of America Securities reiterated a Buy rating on Royalty Pharma (RPRX – Research ...

BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable ...

On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation The Prize includes a ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation The Prize includes a charitable ...

Royalty Pharma Price Performance RPRX stock opened at $25.70 on Friday. Royalty Pharma plc has a 12-month low of $25.10 and a 12-month high of $31.66. The business’s fifty day moving average ...